Since 1987, the GELA has initiated multicenter prospective trials for aggressive non-Hodgkin's lymphomas (NHL). Lymphoblastic lymphomas (LBL) were included in those studies until 1997, and 92 LBL patients under 61 years were identified after histological review. The protocols prescribed high-dose anthracycline regimens, four cycles given every 15 days as induction and lasted for p6 months. A total of 23 patients underwent high-dose therapy consolidation followed by autologous stem-cell transplantation and 69 received standard chemotherapy regimens. Clinical characteristics showed a male predominance (66%) with a median age of 31 years, bone marrow (BM) involvement (22%), mediastinal involvement (66%) and elevated LDH (62%). At the end of treatment, it was seen that 71% of the patients achieved complete remission; four (4%) patients died during induction; 43 patients relapsed at a median time of 10 months. With a median follow-up of 34 months, the 5-year overall survival (OS) and event-free survival (EFS) rates were 32 and 22%, respectively. The only favorable factor significantly associated with survival was young age. These results are poorer than those obtained in other aggressive lymphomas treated with the same regimens and suggest that adult LBL patients should be treated with acute lymphoblastic leukemia protocols.
Introduction
Lymphoblastic lymphomas (LBL) are classified as high-grade nonHodgkin's lymphomas (NHL) in the Working Formulation and represent o2% of NHL. 1 This rare disease occurs mainly in young males and is clinically characterized by frequent mediastinal, pleural, pericardial or meningeal involvement. A large majority (80%) of LBL has a T-cell phenotype. The clinical distinction between LBL and acute lymphoblastic leukemia (ALL) is arbitrary, based on nodal involvement, the degree of bonemarrow (BM) infiltration and the presence of blast cells in the peripheral blood (PB). A patient with a nodal presentation, minimal or no BM involvement and no blast cells in PB is currently diagnosed as having LBL. However, ALL and LBL can be considered as two different manifestations of the same disease. [2] [3] [4] Since LBL are a rare entity, treatment remains uncertain. Different chemotherapy regimens used to treat aggressive lymphoma or ALL have been administrated as induction therapy. 5, 6 Consolidation with chemotherapy or autologous stem-cell transplantation (ASCT) has also been given. 7, 8 Allogeneic stem-cell transplantation is mostly restricted to patients in first complete remission (CR) with a factor of poor risk. 8, 9 The small number of patients with LBL and the difficulty in diagnosing it explain why there are actually very few prospective trial comparing these approaches. From 1987 to 1997, LBL could be included in GELA trials for aggressive lymphomas provided they had no BM or central nervous system (CNS) involvement. We decided to analyze the outcomes of patients under 61 years at diagnosis with LBL confirmed after histological re-examination of the slides from two prospective adult lymphoma trials (LNH87 and LNH93) conducted by the GELA in an attempt to identify prognostic factors for survival.
Materials and methods

Patient selection
From January 1987 to September 1997, 7656 newly diagnosed patients, 16-69 years old, with intermediate or high-grade (HG) NHL, according to the International Working Formulation, were included in the LNH87 or LNH93 trials. These patients were negative for the human immunodeficiency virus, and had no concomitant or previous cancer, uncontrolled diabetes mellitus, congestive heart failure, recent myocardial infarction or conduction abnormalities or kidney dysfunction.
At diagnosis, the patients were staged according to the Ann Arbor system. 10 Disease dissemination was evaluated before treatment by physical examination, BM biopsy, cerebrospinal fluid examination and computed tomography scan of the chest and abdomen, and other investigations according to the clinical symptoms. Performance status (PS) was assessed according to the Eastern Cooperative Oncology Group (ECOG) scale (0-4).
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In the LNH87 study, patients with HG-NHL were stratified into four prognosis groups according to the factors defined by clinical status (age, PS, number of extra nodal sites, tumor burden X10 cm for the largest diameter and BM or CNS involvement). In the LNH93 study, patients with HG-NHL were also stratified into different groups according to the age-adjusted international prognosis index (IPI) for patients p61 years old: lactate dehydrogenase (LDH), stage and PS. 12 LBL patients could be included in these studies provided they had no CNS or BM involvement at inclusion. After giving their informed consent, patients were randomly assigned through a central procedure to the different arms of these trials.
After histological review of the slides of all patients included in the two trials, 120 (1.6%) patients (67 in LNH87 and 53 in LNH93) were finally diagnosed as having LBL. Many of these patients were diagnosed as LBL only after this histological reevaluation of their biopsy, thus explaining why some patients had BM or CNS involvement at diagnosis. Among 99 patients who were p61 years old at initial diagnosis, data were incomplete for seven. Thus, 92 patients were retained for this retrospective analysis.
Histopathology
Three independent hematopathologist members of the GELA performed the histological review and their observations were used to identify LBL patients. Immunophenotype labeling of deparaffinized tissue sections was performed as previously described, using a panel of antibodies directed against B (CD20)-and T (CD3, CD7)-cell-associated antigens. T-or B-LBL was diagnosed based on morphological characteristics and immunophenotyping data. On paraffin sections, T lymphoblasts are TdT and cytoplasm CD3-positive; variably express CD1A, CD2, CD4, CD5 and CD7; frequently coexpress CD4 and CD8; and CD10 may be positive. On paraffin sections, B-lymphoblasts are cytoplasm CD79A-positive and usually CD20-positive. However, in B-cell precursors may be CD20-negative. In most cases, B lymphoblasts are CD10 À , CD34 À and TdT-positive depending on the degree of B-cell lymphoid differentiation.
Treatment
The numbers of patients who received each chemotherapy regimen are summarized in Table 1 . All details of the chemotherapy regimens have been published by the GELA group in a previous report as indicated.
LNH87 protocol (1987-1992)
Patients o55 years received four cycles of ACVBP chemotherapy (adriamycin, cyclophosphamide, vindesin, bleomycin, prednisone and intrathecal (IT) methotrexate, one cycle every 2 weeks for 5-6 months). The response to treatment was evaluated 4 weeks after the last cycle of chemotherapy. Patients with CR or a partial response (PR) were randomly assigned to receive 4 months of consolidation (one cycle every 2 weeks) with standard chemotherapy (methotrexate, ifosfamide and etoposide, L-asparaginase and cytarabine); and methotrexate 3 g/m 2 d1 and d15 followed by high-dose therapy (HDT) with the CBV regimen (cyclophosphamide, BCNU, etoposide) followed by unpurged autologous BM transplantation (BMT). The final evaluation of the protocol, in 1996, found no differences in survival between these two regimens. Only patients with at least two IPI factors of poor prognosis benefited from HDT. 13 Patients 455 years were randomly assigned to receive the ACVBP regimen followed by the same consolidation with standard chemotherapy or an alternative chemotherapy: VIM3 (cycles 1 and 3): mitoxantrone, ifosfamide; mitoguazone; teniposide; methotrexate; prednisone; methotrexate; ACVBP (cycle 2 and 4); VIM (cycles 5 and 7): mitoxantrone, etoposide; ifosfamide; ACVM (cycles 6 and 8): adriamycin, cyclophosphamide, vindesin, methotrexate. At the final evaluation, responses between these two regimens did not differ significantly.
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LNH93 (1993-1997)
Patients o60 years with one of the IPI factor of poor prognosis were enrolled in the LNH93/2 trial and were randomly assigned to receive the ACVBP regimen and consolidation with standard chemotherapy or four cycles of ECVBP (epirubicin; cyclophosphamide; vindesin; bleomycin, prednisone and methotrexate; one cycle every 2 weeks for 5-6 months) and with IVAM (ifosfamide, etoposide, cytarabine; methotrexate). No significant response difference between these two regimens was observed. 15 Patients o60 years with two or three IPI factors of poor prognosis were randomized in the LNH93/3 trial to receive the ACVBP regimen and consolidation with standard chemotherapy or HDT: one cycle of CEOP (cyclophosphamide, epirubicin, vincristin, prednisone, methotrexate), two cycles of ECVBP (one cycle every 2 weeks) followed by PB stem-cell collection, and then a BEAM (BCNU; etoposide, cytarabine, melphalan) followed by ASCT. At the time of the intermediate analysis in 2001, ACVBP was superior to the HDT þ ASCT arm. Thus, all patients were treated with the ACVBP protocol. 16 
Assessment of response
Response to treatment was evaluated 4 weeks after the last cycle of chemotherapy or 4 weeks after HDT. CR was defined as the disappearance of all clinical evidence of disease, the normalization of all laboratories' abnormalities related to the lymphoma, the normalization of radiographic images and biopsies that had been abnormal before therapy. A PR was defined as a regression of X50% in tumor volume. Tumor volume regression of o50% and progressive disease were considered to be failures.
Statistical methods
The study end points were the response rate, the event-free survival (EFS) calculated from the time of randomization to the date of progression, relapse or death and overall survival (OS) measured from the date of randomization to the date of death (regardless of the cause) or the last date of follow-up visit. All analyses were performed on an intention-to-treat basis. Survival rates were estimated using the Kaplan-Meier method and were compared using the log-rank test. 17 The variables analyzed as prognostic indicators were age (o or X40 year and 30 year), LDH (4N ¼ the upper limit of normal and 4500), bulky disease, IPI score, anemia, thrombocytopenia, BM or CNS involvement, T-or B-cell phenotype. Test statistics for comparison of major end points were considered as significant when the two-sided P-value was p0.05. Statistical analyses were conducted using SAS software version 6 (Cary, NC, USA).
Results
Patients' characteristics
The main clinical and biological features of the 92 LBL patients are listed in Table 2 . The median age was 31 years (range: In total, 77 (83%) patients had a T-cell LBL. Four patients (4.3%) were anemic (hemoglobin o10 g/dl) and eight (8.5%) patients were thrombocytopenic (o150 Â 10 9 platelets/l). LDH concentrations were frequently elevated. According to IPI factors, more than half of the patients had low or low-tomoderate risk disease.
Therapeutic results
Responses to treatment are summarized in Table 3 . Almost three-quarters of these LBL patients achieved CR and 12 had PR. These CR and PR rates did not differ significantly among the different chemotherapy regimens. No toxic death was reported; all patients with early death during induction (4%) had persistent evolutive disease. Among the 10 patients with progressive disease who received second-line treatment, similar to ALL chemotherapy, only one patient achieved CR. This latter patient had undergone allogeneic BMT and is still in continuous CR.
We analyzed the outcomes of 43 patients who relapsed (median time to relapse: 10 months (range: 2-30 months)). These patients had been treated with various ALL chemotherapy regimens and 28 achieved a second CR. Among these 28 patients, 24 received an intensification procedure: 10 underwent HDT with ASCT and 14 received allogeneic BMT. Two patients are in continuing CR after ASCT and seven after allogeneic BMT.
EFS, OS and prognostic factors
With a median follow-up of 34 months (range: 1.3-122. months), the 5-years OS and EFS rates were, respectively, 32.3 and 22% (Figure 1a and b) .
We found no difference in outcome according to chemotherapy regimen, HDT or as consolidation (data not shown), BM or CNS involvement or anemia at diagnosis. OS tended to be better for patients in the low or low/intermediate IPI risk groups. Only age statistically improved the EFS (5-year EFS rates: 31.8% for patients p40 years vs 7.7% for patients 440 years, (P ¼ 0.02)) ( Figure 2a ) and OS rates ( Table 4 ). The 5-year OS rates are 43% for patients o41 years vs 12.5% for patients 440 years (P ¼ 0.002) (Figure 2b ).
Discussion
The clinical characteristics of LBL patients analyzed in the present study were similar to those previously described by others: young age patients, male predominance, frequent mediastinal involvement and a large majority of T-cell phenotype. 6, 18 However, CNS and BM involvement in our cohort of patients were more frequent than in other series. 6, 19 This difference can be explained by the misdiagnosis of LBL at first histological examination and the selection of patients for this retrospective analysis after review of pathological diagnosis. Our CR rate with ACVBP was at 71%. Morel et al 6 had reported a cohort of 51 patients treated with CHOP or ACVBP (21 and 30 patients, respectively), with respective CR of 71 and 83%. The small difference between their CR rates and ours might reflect the lower CR rate observed in multicentric studies with unselected patients. In the ECOG trial on adult LBL patients Table 2 Clinical and biological characteristics of the 92 LBL patients included in the LNH87/93 trials Adult lymphoblastic lymphomas S Le Gouill et al with a CHOP-based chemotherapy (CHOP þ L-asparaginase, CNS prophylaxis and maintenance chemotherapy during a 1-year period), 5 CR rate was at 79%. The ECOG patients were younger than ours, with a median age of 26 years (range, 18-62 years). Although comparisons among these different studies remain difficult, the CR rates did not change much (range: 71-79%) and remained much lower than those achieved in children (490%).
Some prognostic factors have been found to significantly affect the survival of patients with LBL: age, stage IV disease, LDH level 4500 or anemia. 6, 18, 19, 20 In our study, age at diagnosis was the only factor to significantly influence the OS rate, in agreement with Morel et al, 40 years appears to be the cut-off for OS and 30 years for Slater et al. 18 Neither CNS nor BM involvement influenced OS and EFS. 19 The age-adjusted IPI score tended to have an effect on OS, but not EFS. A recent article on T-LBL reported the same inability of IPI index to predict LBL outcome. 20 Our 5-year OS and EFS rates of, respectively, 32% and 22% were very poor and much lower than those obtained for other aggressive lymphomas (nearly 50%) 13, 14 or LBL treated with similar regimens, for example, 50% survival for Colgan et al, 19 However, it must be kept in mind that our multicenter study included more unselected patients who were older, had a lower CR rate and a longer follow-up. Other treatment strategies for LBL have been described. With ALL chemotherapy regimens, Slater et al 18 have reported a 5-year OS rate of 45%. More recently, the German BFM group studied 105 children given ALL-type regimens and they estimated the 5-year EFS to be 90%. 21 Comparisons between children and adults with LBL remains difficult, but use of ALL therapies always gave much poorer results in adults. However, compared to aggressive lymphoma chemotherapy, only ALL chemotherapy regimens seem to improve the CR: 80% 22 These encouraging results have to be moderated by the fact that only patients in CR underwent ABMT. Nevertheless, the intensive procedure remains attractive.
The last therapeutic approach is allogeneic BMT. 8 Milpied et al described 12 LBL patients in first CR treated with allogeneic BMT, eight of whom were in continuous CR at the time of evaluation, two had relapsed and two had died. In that report, no OS difference was found between allogeneic and autologous transplantation, in agreement with the retrospective analysis conducted by the European BMT group. 23 Thus, it has not yet been demonstrated that allogeneic transplantation in first CR can prolong the OS. But at relapse, allogeneic transplantation should be considered. In all, 15 of our patients have undergone this procedure because of refractory (n ¼ 1) or relapsed disease (n ¼ 14) and eight of them are still in continuous CR. The limits of allogeneic transplantation in LBL are the same as those for other hematological malignancies: sustained CR before HDT, the need for an HLA-identical donor and high transplant-related mortality because of graft vs host disease.
In conclusion, our study is one of the largest conducted on LBL patients (n ¼ 92) treated with aggressive lymphoma chemotherapy regimens. The age at diagnosis was the only prognostic factor found to influence the OS rates significantly (5-year OS: 42.7% for patients p40 year vs 12.5% for patients 440 year). Owing to the poor results obtained with aggressive lymphoma chemotherapy regimens, we did not include LBL patients in our more recent trials. ALL chemotherapy regimens, which appeared to give better CR and OS rates, will now be prescribed to all LBL patients because we were not able to find a subgroup of good-risk LBL patients. We suggest that allogeneic transplantation, when an HLA-identical sibling is found, could be an option for young patients in first CR with high-risk disease or relapsing patients in second CR. 
